Orthocell Limited (ASX: OCC)
Australia
· Delayed Price · Currency is AUD | Market Cap | 296.71M |
| Revenue (ttm) | 5.32M |
| Net Income (ttm) | -7.18M |
| Shares Out | 239.28M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,745,740 |
| Open | 1.260 |
| Previous Close | 1.250 |
| Day's Range | 1.180 - 1.260 |
| 52-Week Range | 0.350 - 1.270 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2024 |
About Orthocell
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondr... [Read more]
Financial Performance
In 2024, Orthocell's revenue was 5.32 million, an increase of 25.27% compared to the previous year's 4.24 million. Losses were -7.18 million, 14.9% more than in 2023.
Financial StatementsNews
Perth’s billionaire set is piling into this little-known medtech
The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break into the US.